Question · asked by 1 review
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks: Annualized Bleeding Rate (ABR) ‐ All treated bleeds
- Population
- people without inhibitors
- Intervention
- Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly
- Comparison
- emicizumab 3.0 mg/kg every 2 weeks
- Outcome
- Annualized Bleeding Rate (ABR) ‐ All treated bleeds
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly vs emicizumab 3.0 mg/kg every 2 weeks Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (2024) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 71 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.